Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

104.80 +0.48 (+0.46%)

Streaming Delayed Price Updated: 12:13 PM EDT, Mar 26, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	184,996
Open	103.25
Bid (Size)	104.71 (200)
Ask (Size)	104.88 (200)
Prev. Close	104.31
Today's Range	102.47 - 105.69
52wk Range	39.60 - 105.69
Shares Outstanding	62,577,897
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

FDA Approves Protagonist’s ICOTYDE: The Oral Peptide Revolution Hits the Psoriasis Market

March 23, 2026

In a landmark decision for the dermatology sector, the U.S. Food and Drug Administration (FDA) has officially approved ICOTYDE™ (icotrokinra), a first-of-its-kind oral peptide for the treatment of...

Via MarketMinute

This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗

March 21, 2026

This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions.

Via The Motley Fool

Performance

YTD	+20.2%	+20.2%
1 Month	+21.0%	+21.0%
3 Month	+18.0%	+18.0%
6 Month	+58.9%	+58.9%
1 Year	+105.3%	+105.3%

More News

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch ↗

March 21, 2026

Via The Motley Fool

This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund ↗

March 20, 2026

Via The Motley Fool

Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis

March 18, 2026

Via ACCESS Newswire

Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

March 02, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

February 25, 2026

Via ACCESS Newswire

Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

February 25, 2026

Via ACCESS Newswire

Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit ↗

February 25, 2026

Via The Motley Fool

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026

February 24, 2026

Via ACCESS Newswire

Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance ↗

February 16, 2026

Via The Motley Fool

Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes ↗

February 01, 2026

Via The Motley Fool

"Animal Spirits" Return: Morgan Stanley Signals M&A Renaissance as Healthcare and Industrials Lead Shifting Landscape

January 15, 2026

Via MarketMinute

Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026

January 07, 2026

Via ACCESS Newswire

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

January 05, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Protagonist (PTGX) Earnings Call Transcript ↗

November 27, 2025

Via The Motley Fool

Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice

November 27, 2025

Via ACCESS Newswire

Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 06, 2025

Via ACCESS Newswire

Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting

November 03, 2025

Via ACCESS Newswire

What 7 Analyst Ratings Have To Say About Protagonist Therapeutics ↗

October 28, 2025

Via Benzinga

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences

October 27, 2025

Via ACCESS Newswire

Moody Aldrich Dumps Entire Stake in Chart Industries Worth $5.8 Million ↗

October 23, 2025

Via The Motley Fool

Moody Aldrich Fully Exits 136K SKWD Shares Worth $7.8 Million ↗

October 23, 2025

Via The Motley Fool

Moody Aldrich Liquidates Entire Stake in PLMR Worth $8.2 Million ↗

October 21, 2025

Via The Motley Fool

Big Pharma Just Put Peptides Back on the Map – Which Players Are Still Under the Radar?

October 20, 2025

Via AB Newswire

Frequently Asked Questions

Is Protagonist Therapeutics, Inc. - Common Stock publicly traded?

Yes, Protagonist Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Protagonist Therapeutics, Inc. - Common Stock trade on?

Protagonist Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Protagonist Therapeutics, Inc. - Common Stock?

The ticker symbol for Protagonist Therapeutics, Inc. - Common Stock is PTGX on the Nasdaq Stock Market

What is the current price of Protagonist Therapeutics, Inc. - Common Stock?

The current price of Protagonist Therapeutics, Inc. - Common Stock is 104.80

When was Protagonist Therapeutics, Inc. - Common Stock last traded?

The last trade of Protagonist Therapeutics, Inc. - Common Stock was at 03/26/26 12:13 PM ET

What is the market capitalization of Protagonist Therapeutics, Inc. - Common Stock?

The market capitalization of Protagonist Therapeutics, Inc. - Common Stock is 6.56B

How many shares of Protagonist Therapeutics, Inc. - Common Stock are outstanding?

Protagonist Therapeutics, Inc. - Common Stock has 7B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.